GENEWAY.bio was established in 2015 and is headquartered in Jinan. As a popularizer of high-sensitivity molecular detection technology, GENEWAY.bio provides high-sensitivity molecular quantitative solutions for patients with liver diseases and AIDS, helping World achieve the goal of eliminating the public health hazards of viral hepatitis and AIDS by 2030.

        GENEWAY.bio promotes the popular application of high-sensitivity molecular diagnosis technology in the fields of infectious disease clinical diagnosis and monitoring, blood safety molecular screening, preoperative molecular screening, and tumor molecular early screening, helping medical institutions, centers for disease control, blood centers, etc. establish more accurate detection methods and benefit public health.
        We firmly believe that only by promoting the continuous progress of medical technology through innovation is it possible to help more patients restore health and rebuild a better life.
        Detecting important life information in the subtleties and benefiting public health - this is our mission.
        We are - GENEWAY.bio.